A randomized control trial of G-POEM for gastroparesis to assess feasibility, safety, efficacy and physiological mechanisms
A randomized control trial of G-POEM for gastroparesis to assess feasibility, safety, efficacy and physiological mechanisms
批准号:
10211000
负责人:
MICHAEL L. CAMILLERI
金额:
$60.64万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-06-15 至 2025-05-31
关键词:
Abdominal PainAdverse effectsAdvocateAgeAgonistAntralAreaAttentionBody mass indexBotulinum ToxinsCaliberChronicCicatrixClinicClinicalClinical ResearchDataDemographic FactorsDenervationDevicesDiabetes MellitusDiagnosisDiet therapyDiseaseDopamineElectric StimulationEnteralEtiologyFactor AnalysisFibrinogenFunctional disorderFutureGastric EmptyingGastrointestinal MotilityGastroparesisGiant CellsInterstitial Cell of CajalMalnutritionMeasuresMechanicsMetoclopramideMotorNausea and VomitingNeurologicNeuropathyNutritional SupportObstructionOperative Surgical ProceduresOpioid AnalgesicsOralOutcomePathogenesisPathologyPatient SelectionPatient-Focused OutcomesPatientsPharmaceutical PreparationsPhysiologicalPhysiologyPlacebosProceduresPsychological FactorsPyloric sphincter structurePylorusQuestionnairesRandomizedRandomized Controlled TrialsRefractoryRegistriesReportingResistanceRunningSafetySeveritiesSolidStentsStomachSymptomsSyndromeTestingUncertaintyUncontrolled StudyUniversitiesbasecell motilitycontrol trialcostdemographicsdiabeticearly satietyeffective therapyefficacious treatmentexcitatory neuronexperiencegastric retentiongastrointestinal symptomimprovedin vivoinhibitory neuronmacrophagemotility disordernoveloutcome predictionpanaceapredict responsivenessprematurepressureprospectivereduce symptomssham surgerysymptomatic improvementtooltreatment effecttreatment optimization
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
Gastroparesis is defined as a gastrointestinal motility disorder with objectively delayed gastric emptying of
solids in the absence of mechanical obstruction, associated with upper gastrointestinal symptoms including
early satiety, postprandial fullness, nausea, vomiting, bloating, and upper abdominal pain. The
pathophysiology of gastroparesis includes postprandial antral hypomotility and pylorospasm, which may reflect
extrinsic (vagal) denervation, enteric (intrinsic) neuropathy involving excitatory or inhibitory neurons or
electrical syncytium (such as interstitial cells of Cajal) which may result from imbalance of CD206-positive
macrophages that protect these intrinsic mechanisms. The introduction of G-POEM involving endoscopic
pyloromyotomy has focused attention on pyloric dysfunction as a potentially important factor in the
pathogenesis of this syndrome. However, many unknowns remain. First, the reported trials are uncontrolled
with results that are short-term and inconsistent so the true efficacy of this procedure is not clear. Second,
given that it is unlikely that G-POEM is a panacea for all patients, it is important to determine which of several
possible factors influence outcome e.g. etiology (specifically diabetic versus idiopathic gastroparesis);
demographic factors (age, BMI, psychological factors, duration of illness), baseline severity of gastric retention;
gastric dysrhythmia, pyloric distensibility or scarring (as measured by EndoFLIP), postprandial antral motility
and “isolated” pylorospasm (tonic elevation of baseline pressure independent of antral contractions).
Our general hypothesis is that G-POEM is efficacious in relieving some or all symptoms of gastroparesis and
that efficacy differs according to diagnosis, baseline retardation of gastric emptying, antropyloroduodenal
motility and pyloric sphincter diameter and compliance. We will examine this hypothesis in a controlled short-
term study that will inform future, more definitive trials on G-POEM on the optimal patient selection and
outcome criteria. The aims of this pilot and feasibility, hypothesis-generating study are:
Aim 1: To evaluate the 12-month treatment effect of peroral endoscopic pyloromyotomy (G-POEM) vs. sham
surgery in patients with drug-refractory gastroparesis, as measured by validated questionnaires and to perform
a pilot analysis of factors predictive of the outcome including demographics, etiology, vagal dysfunction, in vivo
gastric physiology, (emptying of solids, postprandial antral motility, gastric dysrhythmia and pyloric motor
functions).
Aim 2. To compare the long-term (1 year or more) outcomes in patients randomized to G-POEM with matched
patients prospectively followed in the national Gastroparesis registry run by the Gastroparesis Clinical
Research Consortium (GpCRC).
.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A randomized control trial of G-POEM for gastroparesis to assess feasibility, safety, efficacy and physiological mechanisms
-
批准号:10843438
-
项目类别:
-
资助金额:$51.07万
-
财政年份:2023
-
负责人:MICHAEL L. CAMILLERI
-
依托单位:
Parkinson Disease Neural Circuitry and Gastrointestinal Pathobiology
-
批准号:10740119
-
项目类别:
-
资助金额:$58.43万
-
财政年份:2023
-
负责人:MICHAEL L. CAMILLERI
-
依托单位:
Effect of VNS on Gastric Motor Functions
-
批准号:10610561
-
项目类别:
-
资助金额:$7.58万
-
财政年份:2022
-
负责人:MICHAEL L. CAMILLERI
-
依托单位:
Effect of VNS on Gastric Motor Functions
-
批准号:10709641
-
项目类别:
-
资助金额:$7.58万
-
财政年份:2022
-
负责人:MICHAEL L. CAMILLERI
-
依托单位:
A randomized control trial of G-POEM for gastroparesis to assess feasibility, safety, efficacy and physiological mechanisms
-
批准号:10416023
-
项目类别:
-
资助金额:$59.4万
-
财政年份:2021
-
负责人:MICHAEL L. CAMILLERI
-
依托单位:
Pharmacodynamics, Pharmacogenetics, Clinical Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia
-
批准号:9983012
-
项目类别:
-
资助金额:$37.32万
-
财政年份:2019
-
负责人:MICHAEL L. CAMILLERI
-
依托单位:
Pharmacodynamics, Pharmacogenetics, Clinical Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia
-
批准号:10404023
-
项目类别:
-
资助金额:$37.32万
-
财政年份:2019
-
负责人:MICHAEL L. CAMILLERI
-
依托单位:
Pharmacodynamics, Pharmacogenetics, Clinical Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia
-
批准号:9796963
-
项目类别:
-
资助金额:$37.32万
-
财政年份:2019
-
负责人:MICHAEL L. CAMILLERI
-
依托单位:
Pharmacodynamics, Pharmacogenetics, Clinical Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia
-
批准号:10165708
-
项目类别:
-
资助金额:$37.32万
-
财政年份:2019
-
负责人:MICHAEL L. CAMILLERI
-
依托单位:
Bile Acids, Genetic Control and Colonic Function in Irritable Bowel Syndrome
-
批准号:8536669
-
项目类别:
-
资助金额:$33.1万
-
财政年份:2011
-
负责人:MICHAEL L. CAMILLERI
-
依托单位:
Bile Acids, Genetic Control and Colonic Function in Irritable Bowel Syndrome
-
批准号:8222558
-
项目类别:
-
资助金额:$39.43万
-
财政年份:2011
-
负责人:MICHAEL L. CAMILLERI
-
依托单位:
Bile Acids, Genetic Control and Colonic Function in Irritable Bowel Syndrome
-
批准号:8728203
-
项目类别:
-
资助金额:$34.3万
-
财政年份:2011
-
负责人:MICHAEL L. CAMILLERI
-
依托单位:
Bile Acids, Genetic Control and Colonic Function in Irritable Bowel Syndrome
-
批准号:8325494
-
项目类别:
-
资助金额:$34.3万
-
财政年份:2011
-
负责人:MICHAEL L. CAMILLERI
-
依托单位:
Irritable bowel syndrome-diarrhea: the role of gluten intolerance and HLA-DQ2
-
批准号:7943984
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2009
-
负责人:MICHAEL L. CAMILLERI
-
依托单位:
Cannabinoid Mechanisms in Human Gastrointestinal Motor and Sensory Functions
-
批准号:7934534
-
项目类别:
-
资助金额:$37.62万
-
财政年份:2009
-
负责人:MICHAEL L. CAMILLERI
-
依托单位:
Cannabinoid Mechanisms in Human Gastrointestinal Motor and Sensory Functions
-
批准号:7713946
-
项目类别:
-
资助金额:$37.59万
-
财政年份:2009
-
负责人:MICHAEL L. CAMILLERI
-
依托单位:
Irritable bowel syndrome-diarrhea: the role of gluten intolerance and HLA-DQ2
-
批准号:7814489
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2009
-
负责人:MICHAEL L. CAMILLERI
-
依托单位:
THE EFFECT OF ALVIMOPAN ON GI TRANSIT IN HEALTHY SUBJECTS
-
批准号:7206178
-
项目类别:
-
资助金额:$9.12万
-
财政年份:2005
-
负责人:MICHAEL L. CAMILLERI
-
依托单位:
VSL #3 ON SYMPTOMS AND COLONIC TRANSIT IN PATIENTS WITH ABDOMINAL BLOATING
-
批准号:7206128
-
项目类别:
-
资助金额:$5.33万
-
财政年份:2005
-
负责人:MICHAEL L. CAMILLERI
-
依托单位:
EFFECT OF A MOTILIN AGONIST, BAX-ACC-1638, ON GASTROINTESTINAL MOTOR FUNCTIONS
-
批准号:7206223
-
项目类别:
-
资助金额:$3.77万
-
财政年份:2005
-
负责人:MICHAEL L. CAMILLERI
-
依托单位:
海外基金